Home/Pipeline/NBP-14 (Oncology Program)

NBP-14 (Oncology Program)

Colorectal Cancer

ResearchActive

Key Facts

Indication

Colorectal Cancer

Phase

Research

Status

Active

Company

Neuro Bio

About Neuro Bio

Neuro Bio is a private, preclinical-stage biotech pioneering a disruptive hypothesis for Alzheimer's disease (AD) that challenges the dominant amyloid dogma. The company's core discovery is the T14 peptide, which it posits triggers an aberrant, developmental-like process in specific vulnerable neurons, driving neurodegeneration upstream of amyloid plaque formation. This mechanism informs a dual strategy: a diagnostic pipeline for early detection of T14 in nasal secretions and saliva, and a therapeutic pipeline led by NBP-14, an antagonist of T14. The company is also exploring applications of its platform in oncology, dermatology, and diabetic retinopathy, indicating a broader platform potential.

View full company profile

Therapeutic Areas

Alzheimer's Disease Neurodegenerative Diseases Oncology Dermatology Ophthalmology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
CBI-1214	Cartography Biosciences	Phase 1	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active